DP7U9Chx57 | 353798-90-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: DP7U9Chx57
• 英文别名: (2S)-3-[4-[(7-fluoroquinolin-2-yl)methoxy]phenyl]-2-(quinoline-2-carbonylamino)propanoic acid
• CAS: 353798-90-0
• 化学式: C₂₉H₂₂FN₃O₄
• 分子量: 495.5
• InChiKey: XBKBJNOSNDZQGN-MHZLTWQESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  37
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  101
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• Tyrosine derivatives with anti-leukotrienen activity
  申请人：——

  公开号：US20030087910A1

  公开（公告）日：2003-05-08

  Compounds which can be represented by general formula (I) indicated below and in which: (Formula 1) 1 R 1 and R 2 are selected, independently, from hydrogen, an alkyl group having from 1 to 4 carbon atoms, a halogen group such as a fluoro, chloro or bromo group, the methoxy group, the cyano group, or the trifluoromethyl group, and R 3 is selected, independently, from a phenyl or a 2 (or 3 or 4)-pyridyl group, unsubstituted or mono- or di-substituted with an alkyl or alkoxy group having from 1 to 4 carbon atoms, with a halogen group such as a fluoro or chloro group, with the trifluoromethyl group, with the cyano group, with the nitro group, with the amino group, or with the phenyl group, a 1 (or 2)-naphthyl group, a 2 (or 3)-indolyl group as such or N-alkylated with an alkyl group having from 1 to 3 carbon atoms, a 2 (or 3, 4, 5, 6, 7 or 8)-quinolinyl or a 1 (or 3, 4, 5, 6, 7 or 8)-isoquinolinyl group, unsubstituted or mono- or di-substituted with a group selected, independently, from the methyl, ethyl, propyl, isopropyl, methoxy, fluoro, chloro, trifluoromethyl, cyano, amino, or nitro groups, a 2 (or 5 or 6)-quinoxalyl group, a 3 (or 4, 5, 6, 7 or 8) cinnolyl group, or a 2 (or 4, 5, 6 or 7)-benzimidazolyl group, and in which the configuration of the chiral centre marked with an asterisk (*) in the general formula (I) may be, independently, L, D or DL (racemic).

  以下化合物可以用下面的通式(I)表示，其中： （公式1）1R1和R2分别独立地选择氢、1至4个碳原子的烷基、氟、氯或溴基、甲氧基、氰基或三氟甲基基团，而R3独立地选择苯基或未取代或单取代或双取代1至4个碳原子的烷基或烷氧基、氟或氯基、三氟甲基基团、氰基、硝基、氨基或苯基、1或2-萘基、2-或3-吲哚基或N-烷基化的1至3个碳原子的烷基、2-、3-、4-、5-、6-、7-或8-喹啉基或1-、3-、4-、5-、6-、7-或8-异喹啉基，未取代或单取代或双取代的基团独立地选择甲基、乙基、丙基、异丙基、甲氧基、氟、氯、三氟甲基、氰、氨基或硝基、2-或5-或6-喹嗪基、3-、4-、5-、6-、7-或8-茜素基或2-或4-、5-、6-或7-苯并咪唑基；在通式(I)中用星号（*）标记的手性中心的构型可以独立地为L、D或DL（外消旋）形式。
• TYROSINE DERIVATIVES WITH ANTI-LEUKOTRIENE ACTIVITY
  申请人：ROTTAPHARM S.P.A.

  公开号：EP1255749B1

  公开（公告）日：2007-02-21
• TREATMENTS OF B-CELL PROLIFERATIVE DISORDERS
  申请人：Rickles Richard

  公开号：US20090053168A1

  公开（公告）日：2009-02-26

  The invention provides compositions and methods for the treatment of B-cell proliferative disorders that employ an A2A receptor agonist or one or more PDE inhibitors. The methods and compositions may further include an antiproliferative compound.
• COMBINATIONS FOR THE TREATMENT OF B-CELL PROLIFERATIVE DISORDERS
  申请人：Rickles Richard

  公开号：US20090047243A1

  公开（公告）日：2009-02-19

  The invention features compositions and methods employing combinations of an A2A receptor agonist and a PDE inhibitor for the treatment of a B-cell proliferative disorder, e.g., multiple myeloma.
• G PROTEIN-COUPLED PURINERGIC RECEPTOR Gpr17 MEDIATES OREXIGENIC EFFECTS OF FOXO1 IN AGRP NEURONS
  申请人：THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK

  公开号：US20150087690A1

  公开（公告）日：2015-03-26

  G protein-coupled receptor (GPCR) Gpr17 expressed in hypothalamic Agouti-related peptide-expressing (AgRP) neurons increases appetite and glucose tolerance and insulin sensitivity. By contrast, increasing Gpr17 reduced glucose tolerance and increased appetite. Gpr17-agonists had no effect on FoxO1-deficient mice, indicating, together with other data, that Gpr17 is a Fox-O1 target. Certain embodiments are directed to methods for reducing appetite, increasing glucose tolerance and insulin sensitivity and treating diabetes by administering Gpr17 antagonists or inhibitory oligonucleotides. Appetite can be increased by administering Gpr17 agonists.